597 related articles for article (PubMed ID: 26362631)
1. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
Fontana M; Pica S; Reant P; Abdel-Gadir A; Treibel TA; Banypersad SM; Maestrini V; Barcella W; Rosmini S; Bulluck H; Sayed RH; Patel K; Mamhood S; Bucciarelli-Ducci C; Whelan CJ; Herrey AS; Lachmann HJ; Wechalekar AD; Manisty CH; Schelbert EB; Kellman P; Gillmore JD; Hawkins PN; Moon JC
Circulation; 2015 Oct; 132(16):1570-9. PubMed ID: 26362631
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis.
Lin L; Li X; Feng J; Shen KN; Tian Z; Sun J; Mao YY; Cao J; Jin ZY; Li J; Selvanayagam JB; Wang YN
J Cardiovasc Magn Reson; 2018 Jan; 20(1):2. PubMed ID: 29298704
[TBL] [Abstract][Full Text] [Related]
4. [Late gadolinium enhancement and T1 mapping for the diagnosis of cardiac amyloidosis].
Cui Q; Yu J; Shen W
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Dec; 31(12):1538-1541. PubMed ID: 32029045
[TBL] [Abstract][Full Text] [Related]
5. CMR-based differentiation of AL and ATTR cardiac amyloidosis.
Dungu JN; Valencia O; Pinney JH; Gibbs SD; Rowczenio D; Gilbertson JA; Lachmann HJ; Wechalekar A; Gillmore JD; Whelan CJ; Hawkins PN; Anderson LJ
JACC Cardiovasc Imaging; 2014 Feb; 7(2):133-42. PubMed ID: 24412186
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.
Chatzantonis G; Bietenbeck M; Elsanhoury A; Tschöpe C; Pieske B; Tauscher G; Vietheer J; Shomanova Z; Mahrholdt H; Rolf A; Kelle S; Yilmaz A
Clin Res Cardiol; 2021 Apr; 110(4):555-568. PubMed ID: 33170349
[TBL] [Abstract][Full Text] [Related]
7. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
8. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional phase-sensitive inversion recovery sequencing in the evaluation of left ventricular myocardial scars in ischemic and non-ischemic cardiomyopathy: comparison to three-dimensional inversion recovery sequencing.
Kido T; Kido T; Nakamura M; Kawaguchi N; Nishiyama Y; Ogimoto A; Miyagawa M; Mochizuki T
Eur J Radiol; 2014 Dec; 83(12):2159-2166. PubMed ID: 25311877
[TBL] [Abstract][Full Text] [Related]
10. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis.
Pan JA; Kerwin MJ; Salerno M
JACC Cardiovasc Imaging; 2020 Jun; 13(6):1299-1310. PubMed ID: 32498919
[TBL] [Abstract][Full Text] [Related]
11. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
[TBL] [Abstract][Full Text] [Related]
12. LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis.
Boynton SJ; Geske JB; Dispenzieri A; Syed IS; Hanson TJ; Grogan M; Araoz PA
JACC Cardiovasc Imaging; 2016 Jun; 9(6):680-6. PubMed ID: 27209101
[TBL] [Abstract][Full Text] [Related]
13. Myocardial Edema and Prognosis in Amyloidosis.
Kotecha T; Martinez-Naharro A; Treibel TA; Francis R; Nordin S; Abdel-Gadir A; Knight DS; Zumbo G; Rosmini S; Maestrini V; Bulluck H; Rakhit RD; Wechalekar AD; Gilbertson J; Sheppard MN; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2018 Jun; 71(25):2919-2931. PubMed ID: 29929616
[TBL] [Abstract][Full Text] [Related]
14. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.
Karamitsos TD; Piechnik SK; Banypersad SM; Fontana M; Ntusi NB; Ferreira VM; Whelan CJ; Myerson SG; Robson MD; Hawkins PN; Neubauer S; Moon JC
JACC Cardiovasc Imaging; 2013 Apr; 6(4):488-97. PubMed ID: 23498672
[TBL] [Abstract][Full Text] [Related]
15. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.
Syed IS; Glockner JF; Feng D; Araoz PA; Martinez MW; Edwards WD; Gertz MA; Dispenzieri A; Oh JK; Bellavia D; Tajik AJ; Grogan M
JACC Cardiovasc Imaging; 2010 Feb; 3(2):155-64. PubMed ID: 20159642
[TBL] [Abstract][Full Text] [Related]
16. Synthetic multi-contrast late gadolinium enhancement imaging using post-contrast magnetic resonance fingerprinting.
Rashid I; Al-Kindi S; Rajagopalan V; Walker J; Rajagopalan S; Seiberlich N; Hamilton JI
NMR Biomed; 2024 Jan; 37(1):e5043. PubMed ID: 37740596
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis.
Raina S; Lensing SY; Nairooz RS; Pothineni NV; Hakeem A; Bhatti S; Pandey T
JACC Cardiovasc Imaging; 2016 Nov; 9(11):1267-1277. PubMed ID: 27568115
[TBL] [Abstract][Full Text] [Related]
18. Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis.
Wan K; Sun J; Han Y; Liu H; Yang D; Li W; Wang J; Cheng W; Zhang Q; Zeng Z; Chen Y
Circ J; 2018 Feb; 82(3):739-746. PubMed ID: 29093431
[TBL] [Abstract][Full Text] [Related]
19. Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis.
Kravchenko D; Isaak A; Zimmer S; Öztürk C; Mesropyan N; Bischoff LM; Voigt M; Ginzburg D; Attenberger U; Pieper CC; Kuetting D; Luetkens JA
Eur Heart J Cardiovasc Imaging; 2024 Jun; ():. PubMed ID: 38912832
[TBL] [Abstract][Full Text] [Related]
20. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
Ridouani F; Damy T; Tacher V; Derbel H; Legou F; Sifaoui I; Audureau E; Bodez D; Rahmouni A; Deux JF
J Cardiovasc Magn Reson; 2018 Aug; 20(1):58. PubMed ID: 30115079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
